+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pharmacogenomics. Challenges and Opportunities in Therapeutic Implementation. Edition No. 2

  • ID: 4519360
  • Book
  • December 2018
  • Elsevier Science and Technology

Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation, Second Edition, provides comprehensive coverage of the challenges and opportunities facing the therapeutic implications of pharmacogenomics from academic, regulatory, pharmaceutical, socio-ethical and economic perspectives. While emphasis is on the limitations in moving the science into drug development and direct therapeutic applications, this book also focuses on clinical areas with successful applications and important initiatives that have the ability to further advance the discipline. New chapters cover important topics such as pharmacogenomic data technologies, clinical testing strategies, cost-effectiveness, and pharmacogenomic education and practice guidelines. The importance of ethnicity is also discussed, which highlights phar,acogenomic diversity across Latin American populations.

With chapters written by interdisciplinary experts and insights into the future direction of the field, this book is an indispensable resource for academic and industry scientists, graduate students and clinicians engaged in pharmacogenomics research and therapeutic implementation.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
1. Principles of Pharmacogenomics: Pharmacokinetic, Pharmacodynamic, and Clinical Implications
2. Governmental and Academic Efforts to Advance the Field of Pharmacogenomics
3. Incorporating Pharmacogenomics in Drug Development: Industry and Regulatory Perspectives
4. Translating Pharmacogenomic Research to Therapeutic Potentials
5. Pharmacogenomics in Cancer Therapeutics
6. Pharmacogenomics in Cardiovascular Diseases
7. Pharmacogenomics in Psychiatry Disorders
8. Role of Pharmacogenomics in HIV Infection
9. Role of Pharmacogenomics in Diabetes
10. A Look to the Future: Pharmacogenomics, Pharmacoepigenomics, and System Biology Data Technologies of Today and Tomorrow
11. The Importance of Ethnicity Definitions and Pharmacogenomics in Ethnobridging and Pharmacovigilance
12. Pharmacogenomics in Latin American Population
13. Reactive, Point-of-Care, Pre-emptive and Direct-to-Consumer Pharmacogenomic Testing
14. Economic Evaluation of Pharmacogenomic Testing: Lessons from Psychiatric Pharmacogenomics
15. Pharmacogenomics Education and Clinical Practice Guidelines
Note: Product cover images may vary from those shown
Yui-Wing Francis Lam Professor of Pharmacology, Minnie Stevens Piper Professor (2018), James O'Burke Endowed Centennial, Fellow in Pharmacy, University of Texas Health Science Center, San Antonio, TX, USA. Dr. Lam is Professor of Pharmacology at the University of Texas Health Science Center San Antonio (UTHSCSA). His editing experience included the first edition of Pharmacogenomics as well as being the lead editor of another published book entitled "Herbal Supplements - Drug Interactions. Scientific and Regulatory Perspectives”. He is also a co-author for a book chapter on pharmacogenetics in six consecutive editions of the textbook "Pharmacotherapy: A Pathophysiologic Approach”. Dr. Lam designed and continues to direct a graduate course "Molecular and Pharmacological Basis of Therapeutics” since 2002 for the UTHSCSA and the College of Pharmacy at the University of Texas at Austin. He has organized and participated in international and national symposia on topics related to personalized and molecular medicine, and is a scientific councilor for the Pacific Rim Association for Clinical Pharmacogenetics. Stuart R. Scott Associate Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Division Head, Pharmacogenomics, Sema4, Stamford, CT, USA. Dr. Stuart A. Scott will take on the co-editor role for this second edition. Dr. Scott is an Associate Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai, New York, and is the Division Head of Pharmacogenomics at the Sema4 clinical genetic testing laboratory. His research interests include multiethnic pharmacogenomic allele discovery, cytogenomics, and long-read sequencing method development. He is a member of several international genomic medicine and pharmacogenomics consortia, has co-authored Clinical Pharmacogenetics Implementation Consortium (CPIC) practice guidelines, and is a co-investigator of the Mount Sinai Institute for Personalized Medicine (IPM) pharmacogenomics implementation program. In addition, he teaches pharmacogenomics and clinical genetics to genetic counseling students, graduate and medical students, clinical residents, and fellows by lecturing for several courses at Mount Sinai and other institutions.
Note: Product cover images may vary from those shown